Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic Function

X
Trial Profile

A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic Function

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cilofexor (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Pharmacokinetics
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 01 May 2023 Results (n=56) assessing the pharmacokinetics, pharmacodynamic, safety, and tolerability of cilofexor in participants with normal hepatic function or hepatic impairment, published in the Journal of Clinical Pharmacology.
    • 29 Aug 2020 Results evaluating the short- term safety, pharmacokinetics, and pharmacodynamics of Cilofexor in subjects with mild, moderate, or severe hepatic impairment presented at The International Liver Congress 2020
    • 29 Oct 2018 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top